Is Merck Slimming Down?

Like some of its competitors, Merck is looking to streamline its business and put greater focus on its core products.

Mar 3, 2014 at 11:00AM

Rumor has it that Merck's (NYSE:MRK) consumer care segment may soon be sold, as the company is placing more focus on developing its stronger therapeutic areas. The company's consumer brands include Coppertone sunscreen, Claritin allergy pills and other over-the-counter meds, and Dr. Scholl's foot-care products.

According to Reuters, Merck has begun meeting with buyers and reviewing initial offers; final bids are expected to arrive sometime in late March.

Merck acquired the consumer care segment in 2009 from Schering-Plough, and many market analysts believed the business would eventually be sold. According to The Wall Street Journal, there was even talk of a possible swap with Novartis' vaccine and animal health units, but those close to the matter said that a sale ended up being the best option. Part of the reason is the belief that the consumer health care lines may perform better under a different owner.

Merck's consumer care sales in 2013 were $1.89 billion and made up 4% of the company's total revenue of $44 billion. The segment's sales for 2013 dropped 3% versus 2012's $1.95 billion. Within the segment, allergy medicine Claritin had the highest single- product sales in 2013 of $471 million.

A possible sale of the consumer care business streamlines Merck's business during a time when it's working to revamp its aging pipeline and bounce back from a dry spell in new drug development. The sale, a small portion of Merck's market cap of more than $160 billion, can provide a cash infusion for the company and remove non-core assets from its balance sheet. Merck would be able to focus on its stronger product lines, such as its oncology franchise and vaccines.

Who are the potential buyers?
Reuters reported that offers for the business may come from Reckitt Benckiser, Procter & Gamble (NYSE:PG), and Bayer. Bidding estimates could range between $10 billion and $12 billion. The actual bidding process remains private until a final deal is reached, and the business will probably be sold as an entire unit.

A likely bid may come from a health care player wanting to expand its consumer products line, and adding Merck's consumer care products would be complementary. One of those players could be Reckitt Benckiser -- the company has stated it wants to increase its presence in the consumer health sector and has the financial resources to get the deal done. For fiscal 2013, Reckitt Benckiser's free cash flow increased in excess of net income, and acquisitions are part of its growth strategy. During this time, the company integrated three new brands into its business -- Schiff, BMS, and Guilong.

Procter & Gamble could also benefit from acquiring Merck's consumer health products. At a recent analyst conference, the company mentioned entering "new structurally attractive categories and channels" as one of its core strategies. Acquiring Merck's segment can help this consumer products giant expand beyond its current 75 brands. Merck's product line can help Procter & Gamble's health business include more over-the-counter meds.

Merck's consumer health business would provide these potential suitors with additional exposure to a sector currently dominated by Johnson & Johnson (NYSE:JNJ), which currently holds about 4% market share in consumer health. The company's consumer sales of $14.7 billion for fiscal 2M013 represented an increase of 1.7% from last year. It is a sizable portion of J&J's business and made up 21% of total sales for 2013.

My Foolish conclusion
Merck's last blockbusters were diabetes drug Januvia and cervical cancer vaccine Gardasil, both approved in 2006. Through the sale of its consumer care segment, Merck can place greater focus on guiding its research labs on the development of new drugs. If a successful deal goes through for consumer care, investors could also see a potential future sale of Merck's animal health unit.

Tired of slow growth companies like Merck? Try these on for size.
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.

Eileen Rojas has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson and Procter & Gamble. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers